Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Landray

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
BMJ (Clinical Research Ed.)|December 14, 2002
Evaluating treatment effects reliablyMartin J Landray, Gary Whitlock
BMJ (Clinical Research Ed.)|October 1, 2008
Commentary: Controversies in NICE guidance on chronic kidney diseaseMartin J Landray, Richard J Haynes
Journal of Renal Care|July 1, 2010
Lipids in chronic kidney diseaseDavid Lewis, Richard Haynes, Martin J Landray
Lancet (London, England)|June 12, 2023
Accelerating clinical trials: time to turn words into actionMartin J Landray, Richard Haynes, Christina Reith
The New England Journal of Medicine|November 13, 2014
Niacin for reduction of cardiovascular riskMartin J Landray, Richard Haynes, Jane Armitage
Seminars in Dialysis|November 10, 2007
Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trialsColin Baigent, Martin J Landray, David C Wheeler
Nature Clinical Practice. Nephrology|January 21, 2009
Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomesRichard Haynes, Martin J Landray, Christopher G Winearls
The New England Journal of Medicine|February 10, 2021
Hydroxychloroquine in Hospitalized Patients with Covid-19. ReplyPeter Horby, Nicholas J White, Martin J Landray
Kidney International. Supplement|April 16, 2003
Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) studyDavid C Wheeler, John N Townend, Martin J Landray
Clinical Trials (London, England)|February 6, 2018
Increasing the use of mobile technology-derived endpoints in clinical trialsWilliam G Herrington, Jennifer C Goldsack, Martin J Landray
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
BMJ (Clinical Research Ed.)|December 14, 2002
Evaluating treatment effects reliablyMartin J Landray, Gary Whitlock
BMJ (Clinical Research Ed.)|October 1, 2008
Commentary: Controversies in NICE guidance on chronic kidney diseaseMartin J Landray, Richard J Haynes
Journal of Renal Care|July 1, 2010
Lipids in chronic kidney diseaseDavid Lewis, Richard Haynes, Martin J Landray
Lancet (London, England)|June 12, 2023
Accelerating clinical trials: time to turn words into actionMartin J Landray, Richard Haynes, Christina Reith
The New England Journal of Medicine|November 13, 2014
Niacin for reduction of cardiovascular riskMartin J Landray, Richard Haynes, Jane Armitage
Seminars in Dialysis|November 10, 2007
Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trialsColin Baigent, Martin J Landray, David C Wheeler
Nature Clinical Practice. Nephrology|January 21, 2009
Reassuring results with regard to the effect of donor nephrectomy on cardiovascular outcomesRichard Haynes, Martin J Landray, Christopher G Winearls
The New England Journal of Medicine|February 10, 2021
Hydroxychloroquine in Hospitalized Patients with Covid-19. ReplyPeter Horby, Nicholas J White, Martin J Landray
Kidney International. Supplement|April 16, 2003
Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) studyDavid C Wheeler, John N Townend, Martin J Landray
Clinical Trials (London, England)|February 6, 2018
Increasing the use of mobile technology-derived endpoints in clinical trialsWilliam G Herrington, Jennifer C Goldsack, Martin J Landray
Pageof 12